CEO Executive AssistantEarly clinical development, encompassing first-in-human studies, Phase 1 dose escalation trials, and early Phase 2 proof-of-concept programs, is the highest-risk period in a biotech company’s clinical journey. It is also the period when biotech CEOs most struggle with delegation, because the scientific stakes, investor visibility, and company-defining nature of early data readouts create intense pressure to stay personally close to the work.
This framework provides a structured approach to delegating early clinical development while maintaining the strategic oversight that this critical phase demands. It defines roles, decision authorities, reporting cadences, and escalation protocols that enable the CMO and clinical team to execute excellently while keeping the CEO appropriately informed and engaged.
Framework Foundation: Why Early Clinical Requires Tailored Delegation
Early clinical development has three characteristics that require a tailored delegation approach:
Scientific novelty: First-in-human programs, by definition, involve limited prior human data. Unexpected findings are not just possible; they are expected. The delegation framework must account for both routine program execution and the handling of unexpected safety or efficacy signals.
Investor sensitivity: Early clinical milestones, including program initiation, interim safety reviews, and preliminary efficacy signals, are often investor-facing events with stock price implications. The CEO’s involvement in data interpretation and communication must be carefully designed to maintain integrity while fulfilling investor relations responsibilities.
Speed requirements: Early clinical development is time-competitive. Companies that move faster from preclinical to first-in-human and from Phase 1 to proof-of-concept have significant competitive advantages. Over-centralization of clinical decisions at the CEO level slows the decision cycle in a domain where speed matters enormously.
The delegation framework below addresses all three of these characteristics.
Role Definition
CEO: Owns the early clinical strategy (which programs to advance and on what timeline), the investor and partner narrative for early clinical programs, the board-level reporting on clinical progress, and the organization-level resource decisions that affect the clinical portfolio. Makes final decisions on program advancement or termination above the CMO’s delegated authority.
Chief Medical Officer (CMO): Owns all early clinical program execution, including protocol design, investigator site selection and management, IND submissions and regulatory interactions for Phase 1 programs, data safety monitoring structure, and clinical team leadership. Makes all clinical operational decisions within the approved protocol and budget. Escalates to CEO for defined trigger events.
VP of Clinical Operations: Manages site activation, enrollment logistics, CRO oversight, data management, and operational budget tracking. Reports to CMO. Does not routinely interact with CEO on operational matters.
Chief Scientific Officer (CSO): Partners with CMO on translational science questions connecting preclinical findings to early clinical program design. Co-owns the scientific rationale for early clinical programs. Reports to CEO in parallel to CMO.
Head of Regulatory Affairs: Manages IND and CTA submissions and maintenance, FDA interactions, and protocol amendment filings. Reports to CMO or CSO depending on company structure. CEO involvement in regulatory matters is strategic and exception-based.
Decision Authority Matrix
Decisions made by CEO:
- Advancing a program from preclinical to IND-enabling studies
- Initiating clinical hold discussions with FDA
- Making program termination decisions
- Approving significant changes to the early clinical portfolio that affect capital allocation
- All public disclosures of early clinical data
Decisions made by CMO with CEO notification:
- Protocol amendments that do not change primary endpoints
- Site selection and activation decisions
- CRO selection and contracting within approved budget
- Dose escalation decisions within the approved dose escalation scheme
- Investigator-level safety reviews and responses
Decisions made by CMO without CEO involvement:
- Operational site management decisions
- Clinical monitoring and data management processes
- Clinical staff hiring within approved headcount
- Routine FDA correspondence and query responses
- Protocol query resolutions at the investigator level
Decisions requiring joint CEO-CMO-board scientific committee review:
- Program advancement decisions based on interim data
- Early termination for safety or futility
- Major protocol redesigns that change the scientific hypothesis being tested
Reporting Cadence
Weekly: CMO sends a brief written update to the CEO covering: enrollment status for each active program, any safety events reported in the prior week and their status, any regulatory interactions and outcomes, and any decisions the CMO has made or is making that the CEO should be aware of. This communication should take the CEO less than 10 minutes to review.
Monthly: A structured clinical program review meeting, 60 minutes, where the CMO presents program-specific updates, data emerging from ongoing studies, and any strategic decision points on the horizon. The CEO asks strategic questions and provides direction on any CEO-level decisions. The CSO participates for programs with active translational science questions.
Quarterly: A clinical portfolio review that includes the full clinical leadership team and the board’s scientific committee (or selected board members). This review evaluates portfolio progress, resource allocation, and emerging strategic priorities in early clinical development.
Event-driven: For significant safety events, major efficacy signals, or regulatory actions, the CMO escalates immediately to the CEO, regardless of the regular reporting cadence. Define what constitutes an immediate escalation (any Grade 4 or 5 adverse event, a clinical hold, a preliminary efficacy signal that warrants communicating to investors) versus what can wait for the next scheduled report.
Safety Oversight Delegation Protocol
Safety monitoring is the highest-stakes element of early clinical delegation. The framework for safety oversight should be explicit and non-negotiable.
Data Safety Monitoring Board (DSMB): An independent external committee that reviews unblinded safety data at defined intervals. The DSMB reports to the CMO and through the CMO to the CEO on any significant safety findings. The CEO does not review unblinded data outside of formal DSMB reporting channels.
Serious Adverse Event (SAE) Management: The Clinical Safety team, managed by the CMO, handles all SAE reporting to regulatory agencies, investigators, and the DSMB. The CEO receives a weekly SAE summary without identifiable patient information. Any SAE that may materially affect the program triggers immediate CMO-to-CEO escalation.
Clinical Hold Response: If FDA places a clinical hold on a program, the CEO is immediately involved in the strategic response: resource commitment, communication to investors and board, and the high-level response strategy. The regulatory and clinical teams, led by the CMO, own the detailed response preparation.
For more on how safety and regulatory functions interact in this delegation model, see pharma regulatory affairs, which covers how pharma and biotech CEOs can delegate across regulatory functions while maintaining appropriate oversight of safety-related regulatory obligations.
Investor Communications in Early Clinical Development
Early clinical data disclosure is one of the most sensitive delegation questions for biotech CEOs. The CEO must personally own the investor communication narrative, but the clinical content must be validated by the CMO before use.
Establish a clear protocol: for any investor communication that includes clinical program data, the CMO reviews and validates the scientific accuracy before publication or presentation. The CEO owns the investment thesis framing; the CMO owns the clinical data accuracy. This is a non-negotiable two-person review process that protects both scientific integrity and investor relations.
The CMO should not be the primary investor communicator. Investors are evaluating the CEO’s grasp of the scientific program as well as the data itself. But the CEO who communicates clinical data without CMO review and validation creates both scientific and securities law risk.
Adapting the Framework for Different Company Stages
The framework described above works well for a company with a dedicated CMO and clinical operations team. For earlier-stage companies, adjustments are needed:
Pre-IND stage: The CSO may carry the clinical oversight responsibility before a CMO is hired. The CEO is more directly involved in clinical program design, but should still delegate the operational detail to the most senior clinical person available, even if that is a Clinical Program Manager rather than a CMO.
Post-Phase 1 data, preparing for Phase 2: As the company grows and the clinical program expands, the delegation structure should evolve. The CEO’s direct involvement in clinical program meetings should compress as the CMO’s leadership capacity expands and institutional clinical knowledge deepens.
According to Harvard Business Review analysis of biotech leadership, the most effective biotech CEOs are those who maintain scientific credibility while delegating scientific execution to expert team leaders. This is precisely the balance this delegation framework is designed to achieve.
See pharma CEO delegation guide for a comprehensive view of how the early clinical delegation framework connects to the full range of pharma and biotech CEO delegation responsibilities across the product lifecycle.
Implementing the Framework
Begin implementation by sharing this framework with your CMO and asking them to identify any gaps between the current structure and the framework’s requirements. The most common gaps are: absence of a defined DSMB structure, unclear decision authority at the CMO level, no formal weekly update protocol, and insufficient boundary between CEO strategic involvement and operational clinical management.
Address each gap with a specific action: drafting the decision authority matrix, establishing the reporting template, hiring or contracting for missing expertise, or documenting the escalation triggers. Implementation does not need to happen all at once, but it does need to happen before the next major clinical decision point puts pressure on an underdefined structure.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.